FORTAMET Drug Patent Profile

« Back to Dashboard

When do Fortamet patents expire, and when can generic versions of Fortamet launch?

Fortamet is a drug marketed by Andrx Labs Llc and is included in one NDA.

The generic ingredient in FORTAMET is metformin hydrochloride. Eighty-two suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fortamet

A generic version of FORTAMET was approved as metformin hydrochloride by CHARTWELL on January 24^th, 2002.

Summary for FORTAMET

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FORTAMET

Paragraph IV (Patent) Challenges for FORTAMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FORTAMET	Extended-release Tablets	metformin hydrochloride	500 mg and 1000 mg	021574	1	2008-10-14

US Patents and Regulatory Information for FORTAMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Andrx Labs Llc	FORTAMET	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021574-002	Apr 27, 2004		DISCN	Yes	No
Andrx Labs Llc	FORTAMET	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021574-001	Apr 27, 2004		DISCN	Yes	No

International Patents for FORTAMET

See the table below for patents covering FORTAMET around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	3101999
Australia	739226
Canada	2324493	COMPRIMES ORAUX A NOYAU MONOLITHIQUE A LIBERATION CONTROLEE (CONTROLLED RELEASE ORAL TABLET HAVING A UNITARY CORE)

Supplementary Protection Certificates for FORTAMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1261586	2012C/016	Belgium		PRODUCT NAME: UNE COMBINAISON DE PRODUITS DE SAXAGLIPTINE ET DE METFORMINE AINSI QUE TOUT SELS PHARMACEUTIQUEMENT ACCEPTABLES, DONT LES SELS DE CHLORHYDRATE DE SAXAGLIPTINE ET DE METFORMINE; AUTHORISATION NUMBER AND DATE: EU/1/11/731/001 20111128
1412357	C 2008 016	Romania		PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408
1506211	CR 2014 00037	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116

Investment Scenario and Fundamentals Analysis for FORTAMET

Last updated: February 20, 2026

What is FORTAMET?

FORTAMET is the brand name for metformin hydrochloride, an oral medication primarily used to treat type 2 diabetes. It functions as an insulin sensitizer, reducing hepatic glucose production and improving insulin sensitivity. Its widespread use positions it as a foundational drug in antidiabetic therapy.

Market Overview and Size

The global diabetes drug market was valued at approximately USD 54 billion in 2022. Metformin accounts for roughly 75% of prescriptions for type 2 diabetes, reflecting high sales volume and a low-cost profile. The drug's market involves branded formulations like FORTAMET, and numerous generic versions.

Market Drivers

• Rising prevalence of type 2 diabetes, projected to reach 700 million globally by 2045 (International Diabetes Federation, 2022).
• Increased awareness and diagnosis.
• Cost-effectiveness of metformin compared to newer antidiabetics.
• Expanding indications for metabolic disorders and polycystic ovary syndrome (PCOS).

Market Challenges

• Patent expirations for branded formulations.
• Competition from GLP-1 receptor agonists and SGLT2 inhibitors.
• Regulatory scrutiny over safety concerns (e.g., lactic acidosis risk).

Patent and Regulatory Status

The original patent for branded FORTAMET expired around 2012. This has facilitated a surge in generic options, significantly reducing prices. Current regulatory filings mainly involve generic manufacturers, with no recent patent protections for brand-name versions.

Competitive Landscape

Player	Product	Market Share	Regulatory Status
Original Developer	FORTAMET	Dominant (before 2012)	Patented until 2012
Generics	Multiple	Remaining majority	Approved globally
Other branded drugs	Jardiance, Trulicity	Niche segments	Patent protections ongoing

The generic market suppresses FORTAMET’s revenue potential. However, branded formulations retain value through patient loyalty, formulation improvements, or combination therapies.

Investment Fundamentals

Revenue Trends

Annual sales of branded FORTAMET in the US prior to patent expiry exceeded USD 500 million. Post-expiry, multinational pharmaceutical companies have experienced revenue erosion, with some maintaining brand loyalty via differentiated formulations.

Cost Structure

Manufacturing costs are low due to the drug's simple synthesis. R&D costs are minimal given the drug's age and extensive prior research. Marketing expenses primarily focus on brand differentiation and physician education.

Profitability

The profit margin for FORTAMET-branded versions has declined due to generic competition. Companies with a diversified portfolio of diabetes medications are less exposed.

R&D Pipeline

No recent R&D activity focuses on reformulating FORTAMET itself, but ongoing investigations into extended-release formulations and combination products may offer growth opportunities for existing brands or generics.

Regulatory and Patent Outlook

Regulatory approval of generics continues globally, with bioequivalence establishing market entry. No significant patent protections are active for FORTAMET, which limits exclusivity-based revenue.

Investment Considerations

• Volatility from patent expiry: Revenue declines are imminent for original manufacturers.
• Growth in generic market: Low-cost generics dominate sales, compressing margins.
• Potential for combination therapies: Companies investing in fixed-dose combinations with metformin may sustain revenues.
• Regulatory risks: Safety concerns over lactic acidosis could lead to usage restrictions.

Strategic Implications

Investors should evaluate companies with diversified diabetic drug portfolios or those developing novel formulations or combination therapies involving metformin. Companies solely reliant on FORTAMET branded sales face obsolescence unless they innovate or pivot in the metabolic space.

Key Takeaways

• FORTAMET is a widely prescribed first-line agent for type 2 diabetes with declining revenue prospects due to patent expirations and generic competition.
• The drug’s fundamentals indicate low manufacturing costs but low margins in a saturated market.
• Growth potential lies in combination therapies and formulation innovations rather than the core drug.
• Market dynamics favor generic producers; branded manufacturers face revenue declines.
• Investment risk centers on patent expiry, regulatory safety issues, and market penetration of newer drug classes.

FAQs

1. What is the main revenue driver for FORTAMET?
Generic volume, with limited contribution from branded sales due to patent expiration.

2. Are there new formulations or indications for FORTAMET?
No recent reformulations or novel indications are under development; focus is on generic competition.

3. How does patent expiry affect FORTAMET?
Patent expiry allows generics to enter the market, drastically reducing branded sales and margins.

4. Can FORTAMET regain market share?
Unlikely. Market share erosion is tied to the rise of alternative therapies and the proliferation of generics.

5. What are the investment risks associated with FORTAMET?
Market erosion due to generics, regulatory restrictions related to safety concerns, and limited pipeline activity.

---

References

1. International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th Edition.